KR20220154739A - 상부 얼굴 주름의 치료 - Google Patents

상부 얼굴 주름의 치료 Download PDF

Info

Publication number
KR20220154739A
KR20220154739A KR1020227035398A KR20227035398A KR20220154739A KR 20220154739 A KR20220154739 A KR 20220154739A KR 1020227035398 A KR1020227035398 A KR 1020227035398A KR 20227035398 A KR20227035398 A KR 20227035398A KR 20220154739 A KR20220154739 A KR 20220154739A
Authority
KR
South Korea
Prior art keywords
asn
ile
lys
leu
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227035398A
Other languages
English (en)
Korean (ko)
Inventor
니콜라에 그리고레
케이티 러플
필립 피카우트
Original Assignee
입센 바이오팜 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 입센 바이오팜 리미티드 filed Critical 입센 바이오팜 리미티드
Publication of KR20220154739A publication Critical patent/KR20220154739A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Massaging Devices (AREA)
  • Percussion Or Vibration Massage (AREA)
KR1020227035398A 2020-03-16 2021-03-16 상부 얼굴 주름의 치료 Pending KR20220154739A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2003813.9 2020-03-16
GBGB2003813.9A GB202003813D0 (en) 2020-03-16 2020-03-16 Treatment of upper facial lines
PCT/GB2021/050659 WO2021186167A1 (en) 2020-03-16 2021-03-16 Treatment of upper facial lines

Publications (1)

Publication Number Publication Date
KR20220154739A true KR20220154739A (ko) 2022-11-22

Family

ID=70453766

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227035398A Pending KR20220154739A (ko) 2020-03-16 2021-03-16 상부 얼굴 주름의 치료

Country Status (11)

Country Link
US (2) US20230346674A1 (enExample)
EP (1) EP4120997A1 (enExample)
JP (2) JP2023517727A (enExample)
KR (1) KR20220154739A (enExample)
CN (1) CN115279337A (enExample)
AU (1) AU2021238928A1 (enExample)
BR (1) BR112022018457A2 (enExample)
CA (1) CA3166944A1 (enExample)
GB (1) GB202003813D0 (enExample)
TW (1) TW202140522A (enExample)
WO (1) WO2021186167A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
US12011284B2 (en) * 2020-05-19 2024-06-18 Peachy Corp. Systems and methods for preventing and treating wrinkles
GB202206362D0 (en) * 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of upper facial lines
GB202206361D0 (en) * 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of a facial dystonia
GB202206348D0 (en) * 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of limb spasticity
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
WO2025093845A1 (en) * 2023-11-01 2025-05-08 Ipsen Biopharm Limited Use of high dose chimeric botulinum toxin a for the treatment of upper facial lines
AU2023471835A1 (en) * 2023-11-01 2026-04-30 Ipsen Biopharm Limited Use of chimeric botulinum toxin a for treating blepharospasm and hemifacial spasm
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
DK2154151T3 (da) 2005-09-19 2011-09-05 Allergan Inc Clostridiumtoksinaktiverbare clostridiumtoksiner
EP2524963B1 (en) 2011-05-19 2018-10-31 Ipsen Bioinnovation Limited Methods for the manufacture of proteolytically processed polypeptides
MX359480B (es) 2012-05-30 2018-09-28 President And Fellows Of Harvard College Star Neurotoxina botulínica diseñada.
JP6156954B2 (ja) 2012-11-21 2017-07-05 イプセン バイオイノベーション リミテッド タンパク分解性にプロセシングされたポリペプチドの製造方法
GB201312317D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
GB201407525D0 (en) 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
RU2746736C2 (ru) 2015-03-26 2021-04-20 Президент Энд Феллоуз Оф Гарвард Колледж Сконструированный ботулинический нейротоксин
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins

Also Published As

Publication number Publication date
EP4120997A1 (en) 2023-01-25
GB202003813D0 (en) 2020-04-29
TW202140522A (zh) 2021-11-01
WO2021186167A1 (en) 2021-09-23
US20230346674A1 (en) 2023-11-02
US20260207462A1 (en) 2026-07-23
JP2026097980A (ja) 2026-06-16
CN115279337A (zh) 2022-11-01
AU2021238928A1 (en) 2022-09-01
JP2023517727A (ja) 2023-04-26
CA3166944A1 (en) 2021-09-23
BR112022018457A2 (pt) 2022-11-01

Similar Documents

Publication Publication Date Title
US20230346674A1 (en) Treatment of Upper Facial Lines
TWI825396B (zh) 肢體痙攣之治療
US20250179461A1 (en) Modified Bont/A for Use in the Treatment of a Disorder Affecting an Eyelid Muscle of a Subject
EP4401759B1 (en) Modified bont/a for use in the treatment of cervical dystonia
US20250177278A1 (en) Treatment of upper facial lines
US20250213662A1 (en) Bont/a for use in treating a facial dystonia
RU2846028C1 (ru) Лечение морщин верхней части лица
RU2841585C1 (ru) Модифицированный ботулинический нейротоксин для лечения спастичности конечностей
HK40078498A (en) Treatment of upper facial lines
HK40110371A (en) Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject
HK40114374A (en) Modified bont/a for use in the treatment of cervical dystonia
CN118450899A (zh) 修饰的BoNT/A用于颈肌张力障碍的治疗
CN117979988A (zh) 用于治疗影响受试者眼睑肌肉的疾病的修饰的BoNT/A
HK40078497A (en) Modified botulinum neurotoxin for treating limb spasticity

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902